Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis

Abstract

SUMMARY Background Gut microbiota modifiers may have beneficial effects of non-alcoholic fatty liver disease (NAFLD) but randomised controlled trials (RCT) are lacking in children. Aim We performed a double-blind RCT of VSL#3 vs. placebo in obese children with biopsy-proven NAFLD. Methods Of 48 randomised children, 44 (22 VSL#3 and 22 placebo) completed the study. The main outcome was the change in fatty liver severity at 4 months as detected by ultrasonography. Secondary outcomes were the changes in triglycerides, insulin resistance as detected by the homoeostasis model assessment (HOMA), alanine transaminase (ALT), body mass index (BMI), glucagon-like peptide 1 (GLP-1) and activated GLP-1 (aGLP-1). Ordinal and linear models with cluster confidence intervals were used to evaluate the efficacy of VSL#3 vs. placebo at 4 months. Results At baseline, moderate and severe NAFLD were present in 64% and 36% of PLA children and in 55% and 45% of VSL#3 children. The probability that children supplemented with VSL#3 had none, light, moderate or severe FL at the end of the study was 21%, 70%, 9% and 0% respectively with corresponding values of 0%, 7%, 76% and 17% for the placebo group (P < 0.001). No between-group differences were detected in triglycerides, HOMA and ALT while BMI decreased and GLP-1 and aGLP1 increased in the VSL#3 group (P < 0.001 for all comparisons). Conclusions A 4-month supplement of VSL#3 significantly improves NAFLD in children. The VSL#3-dependent GLP-1 increase could be responsible for these beneficial effects. Trial identifier: NCT01650025 (www.clinicaltrial.gov)

Successful Evolution of a Patient with Obesity, Metabolic Syndrome and Severe Gastro esophageal Reflux after Probiotic Intake

“…A few trials have demonstrated the beneficial effect of some probiotics in nonalcoholic fatty liver disease [16].…”

Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

“…In RCT of VSL#3, "a mixture of eight probiotic strains" compare to placebo in overweight children with biopsy-proven NAFLD, administration of VSL#3 for 4 months significantly improves NAFLD in children (27).…”

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

“…Several proand prebiotics, such as VSL+3, MIYAIRI588, Bifidobacterium bifidum, and Lactobacillus plantarum, and antibiotics may have beneficial effects (143)(144)(145)(146)(147). Nonetheless, conflicting data on VSL+3 suggesting a detrimental effect on hepatic steatosis raise questions about interindividual differences in response to probiotics (148).…”